Brachytherapy and hyperthermia therapy developer BSD Medical of Salt Lake City posted its first-quarter financial results, the company said.
For the quarter (end-November 30), sales revenue increased 109% to $1.4 million, compared with $665,000 for the same period the previous year.
Losses before income taxes decreased by 50%, from $1.3 the previous year to $658,935 for the first quarter, due primarily to the effect of increased sales.
In other news, the company said it received a letter from the U.S. Food and Drug Administration (FDA) regarding its premarket approval (PMA) submission for its BSD-2000 hyperthermia system. The FDA provides guidance as to amendments needed to make the PMA approvable. The company said it could not estimate the impact that the letter will have on the timing of the FDA review process for BSD-2000.
Related Reading
BSD Medical clears first PMA hurtle, August 23, 2007
BSD Medical signs Duke license deal, August 14, 2007
NCCN adds breast cancer hyperthermia therapy to guidelines, December 14, 2006
BSD develops MicroThermX 100, August 29, 2006
BSD gets favorable patent notice, July 26, 2005
Copyright © 2008 AuntMinnie.com
